Quick Answer
AVENUE THERAPEUTICS, INC. reported Total Revenue of $1.40 million for fiscal year 2025.
AVENUE THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.40M | $0.00 | — | — | — | — |
| Net Income | -$2.91M +75.0% |
-$11.65M | — | -$3.55M +4.8% |
-$3.73M +27.6% |
-$5.15M +80.1% |
| Diluted EPS | — | — | — | — | -$0.22 +29.0% |
-$0.31 |
| Total Assets | $2.93M +9.7% |
$2.67M +44.4% |
$1.85M -73.0% |
$6.84M +72.9% |
$3.96M +22.0% |
$3.25M -63.6% |
| Cash and Equivalents | $2.85M +10.1% |
$2.59M +45.5% |
$1.78M -73.4% |
$6.71M +78.3% |
$3.76M +20.1% |
$3.13M -64.2% |
| Stockholders Equity | $1.83M -34.5% |
$2.80M +76.8% |
$1.58M -59.5% |
$3.90M +13.2% |
$3.45M +46.3% |
$2.36M -65.3% |
| R&D Expense | $1.04M -84.4% |
$6.64M +8.4% |
$6.13M +1943.7% |
$300.0K -76.1% |
$1.25M -56.2% |
$2.87M -87.1% |
| Operating Income | -$3.08M +72.7% |
-$11.28M +22.4% |
-$14.54M -80.8% |
-$8.04M -115.2% |
-$3.74M +28.3% |
-$5.21M +80.2% |
| Shares Outstanding | 3.18M +51.0% |
2.11M +517.8% |
341,324 -92.9% |
4.77M +239.5% |
1.41M -91.6% |
16.75M +0.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | -100.0% |
| Net Income | September 30, 2025 | -$683.0K | +77.8% | -303.9% |
| Diluted EPS | September 30, 2023 | $0.06 | +113.3% | +113.3% |
| Total Assets | September 30, 2025 | $3.73M | +41.9% | -10.5% |
| Cash and Equivalents | September 30, 2025 | $3.71M | +42.8% | +11.5% |
| Stockholders Equity | September 30, 2025 | $3.56M | +36.3% | -12.3% |
| R&D Expense | September 30, 2025 | $177.0K | -92.4% | -7.8% |
| Operating Income | September 30, 2025 | -$724.0K | +77.1% | -343.8% |
| Shares Outstanding | September 30, 2025 | 3.18M | +98.5% | +0.0% |
- AVENUE THERAPEUTICS, INC. reported Total Revenue of $1.40 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. reported Net Income of -$2.91 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +75.0% in Net Income compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported Diluted EPS of $0.22 per share (loss) for fiscal year 2021.
- AVENUE THERAPEUTICS, INC. showed an increase of +29.0% in Diluted EPS compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported Total Assets of $2.93 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +9.7% in Total Assets compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported Cash and Equivalents of $2.85 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +10.1% in Cash and Equivalents compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported Stockholders Equity of $1.83 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed a decrease of -34.5% in Stockholders Equity compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported R&D Expense of $1.04 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed a decrease of -84.4% in R&D Expense compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported Operating Income of -$3.08 million for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +72.7% in Operating Income compared to the prior fiscal year.
- AVENUE THERAPEUTICS, INC. reported Shares Outstanding of 3.18 million shares for fiscal year 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +51.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: